From the Chair Magellan Continues to progress its operational and strategic plans. With a focus on a successful laboratory licensing process for the TGA, publication of the results of the Phase 1/2 trial, preparation for the Phase 3 trial in 2025 and ongoing planning for eventual manufacture of cells for our trial and others our […]
Magellan is pleased to announce the results of our Phase 1/2 allogeneic (donor) stem cell trial. The findings are published in Osteoarthritis and Cartilage Open the open-access journal of Osteoarthritis Research Society International (OARSI)
Australia’s Federal Health Minister announces $7 million grant to Magellan Stem Cells
NOTE: Magellan Stem Cells does not treat patients. For those seeking more information on osteoarthritis treatment, please contact our collaborative clinical research partner, Melbourne Stem Cell Centre Research
For more information please email info@magellanstemcells.com.au or call 03 9270 8080
